Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka - LARVOL DELTA

S-1 maintenance chemotherapy following definitive chemoradiotherapy in high-risk locally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. (PubMed, Front Immunol) - "All patients received two to three cycles of TPF (paclitaxel liposome, cisplatin, and fluorouracil) neoadjuvant chemotherapy, followed by concurrent chemoradiotherapy within 1-2 weeks later...Patients with non-keratinizing carcinoma or EBV DNA positivity showed a trend toward improved DMFS as well.Safety:S-1 maintenance chemotherapy demonstrated a favorable safety profile, with only 3.2% of patients experiencing grade 3 adverse events. S-1 maintenance chemotherapy after definitive chemoradiotherapy significantly improves DMFS and OS in patients with high-risk locally advanced NPC, with a favorable safety profile."

Journal • Retrospective data • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC): early safety and efficacy results in participants (pts) from Asia (ESMO Asia 2025) - P3 | "We report early safety and efficacy data within a subgroup of pts from Asia. Pts receive D 1500 mg (first infusion: 60 min; subsequent infusions: 30 min) with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin [O], carboplatin [C], cisplatin [cis], tegafur-gimeracil-oteracil [S-1], cis + S-1, or cis + nab-paclitaxel [P]). In pts from Asia, the safety profiles of all study tx were manageable. Safety results for pts from Asia were comparable to the global TOURMALINE population and TOPAZ-1 study. Interim ORR is promising."

Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial (ESMO Asia 2025) - P2, P3 | "Background: Perioperative chemotherapy containing fluorouracil, oxaliplatin, and docetaxel is preferred for patients with gastric and gastroesophageal junction adenocarcinoma. The KEYNOTE-585 study reported that the neoadjuvant and adjuvant pembrolizumab plus cisplatin-based chemotherapy group achieved a higher pathological complete response rate than the placebo plus cisplatin-based chemotherapy group...The primary endpoint is the pathological complete response rate. Secondary research endpoints include: major pathologic response, objective response rate, R0 resection rate, disease-free survival, overall survival, and safety."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

YOUNG-NEOS: Phase II study of neoadjuvant nab-paclitaxel, oxaliplatin s-1, and sintilimab for resectable early-onset GC/GEJC patients (ESMO Asia 2025) - P2 | "For perioperative backbone chemotherapy in resectable gastric cancer, Japanese and Chinese guidelines recommend a doublet regimen of fluoropyrimidines plus oxaliplatin, while Western guidelines favor a triplet regimen that adds docetaxel...The study is powered at 80% to detect an increase in pCR rate from 6% to 20% with significance level of 0.05. The first patient will be recruited on September 2025, with full accrual expected by September 2027."

Clinical • P2 data • Esophageal Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • HER-2

Real-world effectiveness of chemotherapy regimens in advanced pancreatic cancer: A nationwide, population-based cohort study in Taiwan (ESMO Asia 2025) - "Individuals receiving systemic chemotherapy within 90 days of diagnosis were categorized into treatment groups based on initial regimens: gemcitabine alone, gemcitabine plus nab-paclitaxel, S-1 alone, S-1 plus gemcitabine, FOLFIRINOX, GSL (gemcitabine plus S-1 plus leucovorin), 5-FU–based (5-FU with or without leucovorin), or other... This real-world study highlights the comparative effectiveness of chemotherapy regimens in APC and supports gemcitabine-based combinations as important options in East Asian clinical practice."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Comparative survival and toxicity outcomes of perioperative versus adjuvant chemotherapy in resectable gastric cancer: A real-world cohort study (ESMO Asia 2025) - "Of these, 51 (48%) received NACT with platinum–fluoropyrimidine ± taxane, and 55 (52%) received ADJ with S-1 or capecitabine/oxaliplatin following upfront gastrectomy... Perioperative and adjuvant chemotherapy yielded comparable survival after D2 gastrectomy, though NACT caused higher toxicity. The numerical RFS advantage with adjuvant therapy warrants prospective evaluation. Treatment choice should be individualised."

Clinical • Real-world • Real-world evidence • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Comparison of S-1 with concurrent radiotherapy or gemcitabine plus nab-paclitaxel combination therapy in patients with locally advanced pancreatic cancer: An integrated analysis of two phase II trials (JCOG2408A) (ESMO Asia 2025) - "JCOG1407 was conducted to evaluate the efficacy and safety of GnP and modified FOLFIRINOX... S-1+RT and GnP, whereas OS and DMFS tended to be longer with GnP. Considering that subsequent treatment was less intensive in S-1+RT group, its OS may have been underestimated, suggesting that S-1+RT remains a potential option for patients with LAPC."

Clinical • Combination therapy • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

High pathological response and excellent surgical safety with neoadjuvant radiotherapy plus SOX and sintilimab in locally advanced gastroesophageal junction adenocarcinoma: A prospective single-center study (ESMO Asia 2025) - P=N/A | "Prospective evidence for radiotherapy plus SOX (S-1 and oxaliplatin) with PD-1 blockade in GEJA is limited... Neoadjuvant radiotherapy plus SOX and sintilimab achieved high pCR/MPR rates, 100% R0 resection, and excellent safety in locally advanced GEJA. This triple-modality approach warrants further evaluation in randomized trials and has the potential to redefine the neoadjuvant standard for this population."

Clinical • Metastases • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Neoadjuvant FLOT with or without durvalumab followed by S-1–based adjuvant therapy for gastric cancer: Real-world evidence from Asia (ESMO Asia 2025) - "Background: Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is a Western standard for locally advanced gastric cancer but postoperative tolerability remains suboptimal in Asian patients... Neoadjuvant FLOT with or without durvalumab, followed by S-1–based adjuvant therapy, is feasible and effective in Asian patients with locally advanced or initially unresectable gastric cancer. Durvalumab addition improved R0 resection, ypCR, and conversion surgery rates, supporting a regionally optimized perioperative strategy. These real-world findings warrant validation in prospective, biomarker-driven trials."

Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Real-world evidence on adjuvant S-1 plus docetaxel therapy in stage III gastric cancer (ESMO Asia 2025) - "These findings support the effectiveness and tolerability of S-1 plus docetaxel in clinical practice. Patients with pathological stage III gastric cancer who undergo curative resection with D2 lymphadenectomy may benefit significantly from this adjuvant regimen."

Clinical • HEOR • Real-world • Real-world evidence • Gastric Cancer • Oncology • Solid Tumor

Identification of potential immune biomarkers associating to clinical benefit from intensive chemotherapy combined with serplulimab and trastuzumab in advanced HER2+ gastric cancer: A post-hoc analysis of the ASTRUM study (ESMO Asia 2025) - P2 | "Expolatoring immune biomarkers is essential for patients' straitification and optimizing therapeutic strategy. 40 pts enrolled from July 2022 to September 2024 received S (4.5 mg/kg, D1, Q3W), T (initial 8 mg/kg, D1, then 6 mg/kg, D1, Q3W), and DOS chemotherapy (oxaliplatin 100 mg/m2, docetaxel 40 mg/m2 IV, S-1 40–60 mg BID D1–14 Q3W)... Integrated tumour and circulating immune signatures forecast durable efficacy of treatment. baseline immune biomarkers serve as putatively predictive biomarkers for clinical benefit."

Biomarker • Clinical • IO biomarker • Metastases • Retrospective data • Gastric Cancer • Oncology • Solid Tumor • CCL19 • CD22 • CD8 • CD86 • CRTAM • HER-2 • IL6 • KDR • MMP1 • PGF • TNFRSF18 • XCL2 • ZAP70

Cadonilimab (cado) plus oxaliplatin and tegafur-gimeracil-oteracil potassium (SOX) in resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: A phase II study (Compassion-25) (ESMO Asia 2025) - P2, P3 | "Cado plus SOX effectively reduced tumor burden and had a manageable safety profile in pts with resectable G/GEJ adenocarcinoma. A phase III study of Cado plus SOX as perioperative treatment for these pts is ongoing (NCT07023315)."

IO biomarker • P2 data • Gastroesophageal Junction Adenocarcinoma • Oncology • PD-L1

Real-world outcomes of gemcitabine, cisplatin, and TS-1 (GCS) with or without immunotherapy in advanced biliary tract cancer (ESMO Asia 2025) - "Recent pivotal trials have established triplet regimens of gemcitabine and cisplatin (GC) with immunotherapy, durvalumab in TOPAZ-1 and pembrolizumab in KEYNOTE-966...Patients were categorized into two treatment groups: those receiving GCS alone and those receiving GCS in combination with immunotherapy (durvalumab or nivolumab)... This multicenter real-world study shows that GCS, with or without immunotherapy, is a feasible and effective option for advanced BTC, achieving survival outcomes comparable to or exceeding those in pivotal trials. These findings support GCS as a viable real-world strategy and highlight the need for prospective studies to define its optimal integration with immunotherapy."

Clinical • Metastases • Real-world • Real-world evidence • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Irinotecan, S-1, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer: A single-institute retrospective study (ESMO Asia 2025) - "However, clinical trial and real-world data on this regimen remain limited. In this retrospective study, we evaluated the efficacy and safety of two regimens: a 4-week irinotecan plus S-1 and bevacizumab (IRIS+BEV) regimen, and a 3-week irinotecan plus S-1 and bevacizumab (SIRB) regimen, in patients with mCRC who had failed previous treatment with fluoropyrimidine, oxaliplatin, or bevacizumab... These findings suggest that the combination of bevacizumab with irinotecan and S-1 is an effective and safe second-line therapy in real-world clinical practice for mCRC, consistent with previous small-scale clinical trials."

Metastases • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma (ESMO Asia 2025) - P4 | "Adebrelimab plus SOX demonstrates superior pathological responses versus chemotherapy alone, establishing a promising neoadjuvant regimen for locally advanced gastric adenocarcinoma. Although associated with increased immune-related toxicity, the safety profile remains acceptable."

Clinical • Metastases • Gastric Adenocarcinoma • Oncology • Solid Tumor

KEYNOTE 811: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (clinicaltrials.gov) - P3 | N=738 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Real-world efficacy of gemcitabine plus cisplatin with immune checkpoint inhibitor and with S-1 in biliary tract cancer: A multicenter retrospective study. (ASCO-GI 2026) - "The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Checkpoint inhibition • Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Biliary Cancer • Biliary Tract Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results of JCOG1704. (ASCO-GI 2026) - "Funded by The National Cancer Center Research and Development in Japan Clinical Trial Registration Number: jRCTs031180028 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A multicenter phase II trial of ramucirumab plus irinotecan in patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S-1 therapy: RAMIEL trial (OGSG1901). (ASCO-GI 2026) - "Clinical Trial Registration Number: jRCTs051190071 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial. (ASCO-GI 2026) - P3 | "Clinical Trial Registration Number: NCT01795027 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • P3 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology

Phase 2 feasibility study of adjuvant chemotherapy with cisplatin (CDDP) and TS-1, followed by alternate-day TS-1 maintenance therapy, in patients with completely resected pathological stage II-IIIA non-small cell lung cancer. (PubMed, J Thorac Dis) - "Among these regimens, cisplatin plus vinorelbine (CDDP + VNR) has been most frequently used in Japan and shown to improve survival, but it is associated with significant toxicity that often limits treatment completion...This phase 2 study suggests that adjuvant therapy with CDDP + TS-1 followed by TS-1 monotherapy administered on alternate days is a feasible and relatively well-tolerated treatment regimen for patients with completely resected stage II-III NSCLC. The completion rate of the full protocol, survival outcomes, and limited AEs support the potential use of this regimen as a viable alternative within platinum-based adjuvant chemotherapy strategies."

Journal • P2 data • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Adjuvant S-1 combined with durvalumab in resectable biliary tract cancer : a prospective, single-arm phase II trial [WITHDRAWN] (ESMO Asia 2025) - No abstract available

Clinical • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy (clinicaltrials.gov) - P3 | N=204 | Completed | Sponsor: Shanghai Cancer Hospital, China | Recruiting ➔ Completed | N=682 ➔ 204

Enrollment change • Trial completion • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Long-term survival after solitary ocular metastasis following radical resection of esophagogastric junction carcinoma: a rare case report. (PubMed, Front Oncol) - "Following multidisciplinary team (MDT) discussion, a combined treatment plan was implemented, starting with systemic therapy consisting of docetaxel, tegafur/gimeracil/oteracil (S-1), and tislelizumab. This case highlights that integrated multimodal therapy-including systemic and local interventions-can result in long-term survival for patients with isolated ocular metastasis from EGJ cancer. MDT-based, individualized treatment planning is essential for optimizing outcomes in rare metastatic scenarios and may inform future precision oncology approaches."

Journal • Esophageal Cancer • Gastric Cancer • Oncology

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (clinicaltrials.gov) - P3 | N=320 | Not yet recruiting | Sponsor: Genfleet Therapeutics (Shanghai) Inc.

Monotherapy • New P3 trial • Oncology • Pancreatic Cancer • Solid Tumor • KRAS